OTLK
OUTLOOK THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q1 2025(8Q snapshot) | 5Q | $1.84 | $0.23 | -88% |
| Point72 Asset Management | Q2 2026(8Q snapshot) | 1Q | $0.23 | $0.23 | +0% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q3 2025 | Q2 2026 | → $0.23 | -91% |
| Two Sigma Investments 2× in & out | Q4 2025 | Q1 2026 | → $0.42 | -73% |
| AQR Capital Management 2× in & out | Q1 2025 | Q4 2025 | → $1.57 | -16% |
| Citadel Advisors | Q1 2025 | Q2 2025 | → $1.67 | -10% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Outlook Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001649989-26-000005Jun 3, 2026
- Form 40000899140-26-000620Jun 1, 2026
- Form 40001649989-26-000004May 27, 2026
- Form 40001649989-26-000003May 27, 2026
- Form 40001649989-26-000002May 27, 2026
- Form 40001649989-26-000001May 27, 2026
- Form 40001649989-25-000010Oct 3, 2025
- Form 40001649989-25-000009Oct 3, 2025
- Form 40001649989-25-000008Oct 3, 2025
- Form 40001649989-25-000007Oct 3, 2025
- Form 40001649989-25-000006Oct 3, 2025
- Form 40001649989-25-000005Oct 3, 2025
- Form 40001649989-25-000004Oct 3, 2025
- Form 40001649989-25-000003Oct 3, 2025
- Form 40001415889-25-019586Jul 9, 2025
Fundamentals
XBRL · OUTLOOK THERAPEUTICS, INC.Annual figures sourced directly from OUTLOOK THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Outlook Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- DEF 14AProxy statementJun 1, 2026
- 8-KFORM 8-KJun 1, 2026
- 8-KFORM 8-KMay 29, 2026
- 8-KFORM 8-KMay 28, 2026
- 8-KFORM 8-KMay 26, 2026
- 8-KFORM 8-KMay 18, 2026
- 10-QQuarterly reportMay 15, 2026
- 8-KFORM 8-KMay 13, 2026
- 8-KFORM 8-KApr 23, 2026
- 8-KFORM 8-KApr 21, 2026
- 8-KFORM 8-KApr 7, 2026
- 8-KFORM 8-KMar 25, 2026
- 8-KFORM 8-KMar 16, 2026
- 8-KFORM 8-KMar 11, 2026
- 8-KFORM 8-KMar 10, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q2 2026 | open | $0.23 | $0.23 | +0% |
| Renaissance Technologies | Q2 2026 | open | $0.23 | $0.23 | -2% |
| Two Sigma Investments | Q4 2025 | Q1 2026 | $1.57 | $0.42 | -73% |
| Millennium Management | Q3 2025 | Q2 2026 | $2.43 | $0.23 | -91% |
| Renaissance Technologies | Q3 2025 | Q4 2025 | $2.13 | $1.47 | -31% |
| Citadel Advisors | Q1 2025 | Q2 2025 | $1.87 | $1.67 | -10% |
| Two Sigma Investments | Q1 2025 | Q3 2025 | $1.87 | $2.43 | +30% |
| AQR Capital Management | Q1 2025 | Q4 2025 | $1.87 | $1.57 | -16% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | $1.84 | $1.75 | -5% |
| AQR Capital Management | Q3 2024 | Q4 2024 | $7.34 | $5.51 | -25% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.